Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272063 · ClinicalTrials.gov registry record
Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography
A clinical trial, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- 91
- Enrollment target
NCT01272063: Completed study, sponsored by Carl Zeiss Meditec.
NCT01272063 is a clinical trial that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 91 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272063 has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
Study Summary
The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-02 |
What the finished NCT01272063 record still lists
NCT01272063 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01272063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01272063 about?
NCT01272063 is a clinical study titled "Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography". The objective of this study is to compare the areas designated as elevated retinal pigment epithelium (RPE) by the Cirrus HD-OCT versus those designated as drusen on color fundus photographs (CFPs).
What is the current status of trial NCT01272063?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2010-11. Estimated completion is 2011-02.
Who is sponsoring clinical trial NCT01272063?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia